Choate Investment Advisors trimmed its stake in Amgen Inc. by 9.0% during Q4, selling 1,579 shares and holding 15,990 shares worth $4.17 million. Meanwhile, other major institutional investors, like ...
24/7 Wall St. on MSN3h
2025’s Five Highest Yielding Dogs of the Dow Could Explode HigherThe ‘Dogs of the Dow’ is a well-known strategy first published in 1991 by Michael Higgins. The plan seeks to maximize the ...
The massive pharmacy benefit manager plans to stop requiring coverage authorizations for roughly 80 drugs used to treat ...
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...
AGD members are using the population-level insights to uncover novel drug targets SAN DIEGO, /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical ...
UnitedHealth Group's pharmacy benefit manager, Optum Rx, said on Wednesday it would ease requirements to get insurance ...
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback